查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1402887

女性健康市場 - 全球產業分析、規模、佔有率、成長、趨勢和預測，2023-2031 年

Women's Health Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

女性健康市場 - 報告範圍

TMR 關於全球女性健康市場的報告研究了過去以及當前的成長趨勢和機會，以獲得 2023 年至 2031 年預測期內市場指標的寶貴見解。該報告提供了全球女性健康市場的收入2017-2031年期間，考慮2023年為基準年，2031年為預測年。報告中也提供了2023年至2031年全球女性健康市場的年複合成長率（CAGR %）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解女性健康市場。

市場概況
2023年市場價值 778 億美元
2031 年市場價值 1,309 億美元
CAGR 5.5%

該報告深入探討了全球女性健康市場的競爭格局。全球女性健康市場的主要參與者已經確定，並且每位參與者都根據不同的屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球女性健康市場參與者的屬性。

目錄

第 1 章：執行摘要

第 2 章：假設與研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概覽

  • 市場區隔
  • 概述
  • 市場動態
  • 2023-2031年全球市場分析與預測

第 5 章：關鍵見解

  • 管道分析
  • 女性常見健康問題清單
  • 全球主要國家的疾病盛行率和發生率
  • COVID-19 大流行對該行業的影響

第 6 章：市場分析與預測：依治療類型

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：依治療類型，2023-2031
    • 荷爾蒙治療
      • 雌激素治療
      • 黃體素治療
      • 聯合療法
      • 甲狀腺替代療法
      • 副甲狀腺素治療
      • 其他
    • 非荷爾蒙治療
      • 標靶治療藥物
      • 抗生素
      • 雙磷酸鹽
      • 其他
  • 市場吸引力：按治療類型

第 7 章：全球市場分析與預測：按疾病適應症

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：依疾病適應症，2023-2031
    • 癌症
      • 乳癌
      • 子宮頸癌
      • 卵巢癌
    • 甲狀腺功能低下症
    • 停經後綜合症
    • 骨質疏鬆症
    • 避孕
    • 子宮肌瘤
    • 泌尿道感染
    • 其他
  • 市場吸引力：依疾病適應症分類

第 8 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2023-2031
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力：按地區

第 9 章：北美市場分析與預測

第 10 章：歐洲市場分析與預測

第 11 章：亞太市場分析與預測

第 12 章：拉丁美洲市場分析與預測

第 13 章：中東和非洲市場分析與預測

第 14 章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 市佔率分析：依公司分類（2022 年）
  • 公司簡介
    • Eli Lilly and Company
    • Novartis AG
    • Pfizer, Inc.
    • Merck & Co., Inc.
    • Novo Nordisk A/S
    • Amgen Inc.
    • AstraZeneca
    • F. Hoffmann-La Roche Ltd
    • Sanofi
    • Allergan Plc.
    • GlaxoSmithKline plc
    • Lupin Pharmaceuticals, Inc.
Product Code: TMRGL214

Women's Health Market - Scope of Report

TMR's report on the global women's health market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global women's health market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global women's health market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the women's health market.

Market Snapshot
Market Value in 2023US$ 77.8 Bn
Market Value in 2031US$ 130.9 Bn
CAGR5.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global women's health market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global women's health market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global women's health market.

The report delves into the competitive landscape of the global women's health market. Key players operating in the global women's health market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global women's health market profiled in this report.

Key Questions Answered in Global women's health Market Report:

  • What is the sales/revenue generated by women's health across all regions during the forecast period?
  • What are the opportunities in the global women's health market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Women's Health Market - Research Objectives and Research Approach

The comprehensive report on the global women's health market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global women's health market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global women's health market.

Table of Contents

1. Executive Summary

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Women's Health Market

4. Market Overview

  • 4.1. Market Segmentation
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Women's Health Market Analysis and Forecast, 2023-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. List of Common Health Issues Among Women
  • 5.3. Disease Prevalence & Incidence Rate Globally With Key Countries
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Women's Health Market Analysis and Forecast, by Treatment Type

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Treatment Type, 2023-2031
    • 6.3.1. Hormonal Treatment
      • 6.3.1.1. Estrogen Therapy
      • 6.3.1.2. Progestin Therapy
      • 6.3.1.3. Combination Therapy
      • 6.3.1.4. Thyroid Replacement Therapy
      • 6.3.1.5. Parathyroid Hormone Therapy
      • 6.3.1.6. Others
    • 6.3.2. Non-Hormonal Treatment
      • 6.3.2.1. Targeted Therapy Drugs
      • 6.3.2.2. Antibiotics
      • 6.3.2.3. Bisphosphonates
      • 6.3.2.4. Others
  • 6.4. Market Attractiveness, by Treatment Type

7. Global Women's Health Market Analysis and Forecast, by Disease Indication

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Disease Indication, 2023-2031
    • 7.3.1. Cancer
      • 7.3.1.1. Breast Cancer
      • 7.3.1.2. Cervical Cancer
      • 7.3.1.3. Ovarian Cancer
    • 7.3.2. Hypothyroidism
    • 7.3.3. Post-Menopausal Syndrome
    • 7.3.4. Osteoporosis
    • 7.3.5. Contraception
    • 7.3.6. Uterine Fibroid
    • 7.3.7. Urinary Tract Infection
    • 7.3.8. Others
  • 7.4. Market Attractiveness, by Disease Indication

8. Global Women's Health Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region, 2023-2031
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness, by Region

9. North America Women's Health Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Treatment Type, 2023-2031
    • 9.2.1. Hormonal Treatment
      • 9.2.1.1. Estrogen Therapy
      • 9.2.1.2. Progestin Therapy
      • 9.2.1.3. Combination Therapy
      • 9.2.1.4. Thyroid Replacement Therapy
      • 9.2.1.5. Parathyroid Hormone Therapy
      • 9.2.1.6. Others
    • 9.2.2. Non-Hormonal Treatment
      • 9.2.2.1. Targeted Therapy Drugs
      • 9.2.2.2. Antibiotics
      • 9.2.2.3. Bisphosphonates
      • 9.2.2.4. Others
  • 9.3. Market Value Forecast, by Disease Indication, 2023-2031
    • 9.3.1. Cancer
      • 9.3.1.1. Breast Cancer
      • 9.3.1.2. Cervical Cancer
      • 9.3.1.3. Ovarian Cancer
    • 9.3.2. Hypothyroidism
    • 9.3.3. Post-Menopausal Syndrome
    • 9.3.4. Osteoporosis
    • 9.3.5. Contraception
    • 9.3.6. Uterine Fibroid
    • 9.3.7. Urinary Tract Infection
    • 9.3.8. Others
  • 9.4. Market Value Forecast, by Country, 2023-2031
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. Market Attractiveness Analysis
      • 9.5.1.1. By Treatment Type
      • 9.5.1.2. By Disease Indication
      • 9.5.1.3. By Country

10. Europe Women's Health Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Treatment Type, 2023-2031
    • 10.2.1. Hormonal Treatment
      • 10.2.1.1. Estrogen Therapy
      • 10.2.1.2. Progestin Therapy
      • 10.2.1.3. Combination Therapy
      • 10.2.1.4. Thyroid Replacement Therapy
      • 10.2.1.5. Parathyroid Hormone Therapy
      • 10.2.1.6. Others
    • 10.2.2. Non-Hormonal Treatment
      • 10.2.2.1. Targeted Therapy Drugs
      • 10.2.2.2. Antibiotics
      • 10.2.2.3. Bisphosphonates
      • 10.2.2.4. Others
  • 10.3. Market Value Forecast, by Disease Indication, 2023-2031
    • 10.3.1. Cancer
      • 10.3.1.1. Breast Cancer
      • 10.3.1.2. Cervical Cancer
      • 10.3.1.3. Ovarian Cancer
    • 10.3.2. Hypothyroidism
    • 10.3.3. Post-Menopausal Syndrome
    • 10.3.4. Osteoporosis
    • 10.3.5. Contraception
    • 10.3.6. Uterine Fibroid
    • 10.3.7. Urinary Tract Infection
    • 10.3.8. Others
  • 10.4. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Italy
    • 10.4.5. Spain
    • 10.4.6. Rest of Europe
  • 10.5. Market Attractiveness Analysis
      • 10.5.1.1. By Treatment Type
      • 10.5.1.2. By Disease Indication
      • 10.5.1.3. By Country/Sub-region

11. Asia Pacific Women's Health Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Treatment Type, 2023-2031
    • 11.2.1. Hormonal Treatment
      • 11.2.1.1. Estrogen Therapy
      • 11.2.1.2. Progestin Therapy
      • 11.2.1.3. Combination Therapy
      • 11.2.1.4. Thyroid Replacement Therapy
      • 11.2.1.5. Parathyroid Hormone Therapy
      • 11.2.1.6. Others
    • 11.2.2. Non-Hormonal Treatment
      • 11.2.2.1. Targeted Therapy Drugs
      • 11.2.2.2. Antibiotics
      • 11.2.2.3. Bisphosphonates
      • 11.2.2.4. Others
  • 11.3. Market Value Forecast, by Disease Indication, 2023-2031
    • 11.3.1. Cancer
      • 11.3.1.1. Breast Cancer
      • 11.3.1.2. Cervical Cancer
      • 11.3.1.3. Ovarian Cancer
    • 11.3.2. Hypothyroidism
    • 11.3.3. Post-Menopausal Syndrome
    • 11.3.4. Osteoporosis
    • 11.3.5. Contraception
    • 11.3.6. Uterine Fibroid
    • 11.3.7. Urinary Tract Infection
    • 11.3.8. Others
  • 11.4. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Treatment Type
    • 11.5.2. By Disease Indication
    • 11.5.3. By Country/Sub-region

12. Latin America Women's Health Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Treatment Type, 2023-2031
    • 12.2.1. Hormonal Treatment
      • 12.2.1.1. Estrogen Therapy
      • 12.2.1.2. Progestin Therapy
      • 12.2.1.3. Combination Therapy
      • 12.2.1.4. Thyroid Replacement Therapy
      • 12.2.1.5. Parathyroid Hormone Therapy
      • 12.2.1.6. Others
    • 12.2.2. Non-Hormonal Treatment
      • 12.2.2.1. Targeted Therapy Drugs
      • 12.2.2.2. Antibiotics
      • 12.2.2.3. Bisphosphonates
      • 12.2.2.4. Others
  • 12.3. Market Value Forecast, by Disease Indication, 2023-2031
    • 12.3.1. Cancer
      • 12.3.1.1. Breast Cancer
      • 12.3.1.2. Cervical Cancer
      • 12.3.1.3. Ovarian Cancer
    • 12.3.2. Hypothyroidism
    • 12.3.3. Post-Menopausal Syndrome
    • 12.3.4. Osteoporosis
    • 12.3.5. Contraception
    • 12.3.6. Uterine Fibroid
    • 12.3.7. Urinary Tract Infection
    • 12.3.8. Others
  • 12.4. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Treatment Type
    • 12.5.2. By Disease Indication
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Women's Health Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Treatment Type, 2023-2031
    • 13.2.1. Hormonal Treatment
      • 13.2.1.1. Estrogen Therapy
      • 13.2.1.2. Progestin Therapy
      • 13.2.1.3. Combination Therapy
      • 13.2.1.4. Thyroid Replacement Therapy
      • 13.2.1.5. Parathyroid Hormone Therapy
      • 13.2.1.6. Others
    • 13.2.2. Non-Hormonal Treatment
      • 13.2.2.1. Targeted Therapy Drugs
      • 13.2.2.2. Antibiotics
      • 13.2.2.3. Bisphosphonates
      • 13.2.2.4. Others
  • 13.3. Market Value Forecast, by Disease Indication, 2023-2031
    • 13.3.1. Cancer
      • 13.3.1.1. Breast Cancer
      • 13.3.1.2. Cervical Cancer
      • 13.3.1.3. Ovarian Cancer
    • 13.3.2. Hypothyroidism
    • 13.3.3. Post-Menopausal Syndrome
    • 13.3.4. Osteoporosis
    • 13.3.5. Contraception
    • 13.3.6. Uterine Fibroid
    • 13.3.7. Urinary Tract Infection
    • 13.3.8. Others
  • 13.4. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Treatment Type
    • 13.5.2. By Disease Indication
    • 13.5.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 14.2. Market Share Analysis, by Company (2022)
  • 14.3. Company Profiles
    • 14.3.1. Eli Lilly and Company
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. Financial Overview
      • 14.3.1.4. SWOT Analysis
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Novartis AG
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. Financial Overview
      • 14.3.2.4. SWOT Analysis
      • 14.3.2.5. Strategic Overview
    • 14.3.3. Pfizer, Inc.
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. Financial Overview
      • 14.3.3.4. SWOT Analysis
      • 14.3.3.5. Strategic Overview
    • 14.3.4. Merck & Co., Inc.
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. Financial Overview
      • 14.3.4.4. SWOT Analysis
      • 14.3.4.5. Strategic Overview
    • 14.3.5. Novo Nordisk A/S
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. Financial Overview
      • 14.3.5.4. SWOT Analysis
      • 14.3.5.5. Strategic Overview
    • 14.3.6. Amgen Inc.
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. Financial Overview
      • 14.3.6.4. SWOT Analysis
      • 14.3.6.5. Strategic Overview
    • 14.3.7. AstraZeneca
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. Financial Overview
      • 14.3.7.4. SWOT Analysis
      • 14.3.7.5. Strategic Overview
    • 14.3.8. F. Hoffmann-La Roche Ltd
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. Financial Overview
      • 14.3.8.4. SWOT Analysis
      • 14.3.8.5. Strategic Overview
    • 14.3.9. Sanofi
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Product Portfolio
      • 14.3.9.3. Financial Overview
      • 14.3.9.4. SWOT Analysis
      • 14.3.9.5. Strategic Overview
    • 14.3.10. Allergan Plc.
      • 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.10.2. Product Portfolio
      • 14.3.10.3. Financial Overview
      • 14.3.10.4. SWOT Analysis
      • 14.3.10.5. Strategic Overview
    • 14.3.11. GlaxoSmithKline plc
      • 14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.11.2. Product Portfolio
      • 14.3.11.3. Financial Overview
      • 14.3.11.4. SWOT Analysis
      • 14.3.11.5. Strategic Overview
    • 14.3.12. Lupin Pharmaceuticals, Inc.
      • 14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.12.2. Product Portfolio
      • 14.3.12.3. Financial Overview
      • 14.3.12.4. SWOT Analysis
      • 14.3.12.5. Strategic Overview

List of Tables

  • Table 01: Global Women's Health Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
  • Table 02: Global Women's Health Market Value (US$ Mn) Forecast, by Disease Indication, 2023-2031
  • Table 03: Global Women's Health Market Value (US$ Mn) Forecast, by Region, 2023-2031
  • Table 04: North America Women's Health Market Value (US$ Mn) Forecast, by Country, 2023-2031
  • Table 05: North America Women's Health Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
  • Table 06: North America Women's Health Market Value (US$ Mn) Forecast, by Disease Indication, 2023-2031
  • Table 07: Europe Women's Health Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 08: Europe Women's Health Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
  • Table 09: Europe Women's Health Market Value (US$ Mn) Forecast, by Disease Indication 2023-2031
  • Table 10: Asia Pacific Women's Health Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 11: Asia Pacific Women's Health Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
  • Table 12: Asia Pacific Women's Health Market Value (US$ Mn) Forecast, by Disease Indication, 2023-2031
  • Table 13: Latin America Women's Health Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 14: Latin America Women's Health Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
  • Table 15: Latin America Women's Health Market Value (US$ Mn) Forecast, by Disease Indication 2023-2031
  • Table 16: Middle East & Africa Women's Health Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 17: Middle East & Africa Women's Health Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
  • Table 18: Middle East & Africa Women's Health Market Value (US$ Mn) Forecast, by Disease Indication 2023-2031

List of Figures

  • Figure 01: Global Women's Health Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 02: Global Women's Health Market Value Share, by Treatment Type, 2022
  • Figure 03: Global Women's Health Market Value Share, by Disease Indication, 2022
  • Figure 04: Global Women's Health Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 05: Global Women's Health Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 06: Global Women's Health Market Value Share Analysis, by Disease Indication, 2022 and 2031
  • Figure 07: Global Women's Health Market Attractiveness Analysis, by Disease Indication 2023-2031
  • Figure 08: Global Women's Health Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 09: Global Women's Health Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 10: North America Women's Health Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 11: North America Women's Health Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 12: North America Women's Health Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 13: North America Women's Health Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 14: North America Women's Health Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 15: North America Women's Health Market Value Share Analysis, by Disease Indication, 2022 and 2031
  • Figure 16: North America Women's Health Market Attractiveness Analysis, by Disease Indication 2023-2031
  • Figure 17: Europe Women's Health Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 18: Europe Women's Health Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 19: Europe Women's Health Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 20: Europe Women's Health Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 21: Europe America Women's Health Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 22: Europe Women's Health Market Value Share Analysis, by Disease Indication, 2022 and 2031
  • Figure 23: Europe Women's Health Market Attractiveness Analysis, by Disease Indication 2023-2031
  • Figure 24: Asia Pacific Women's Health Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 25: Asia Pacific Women's Health Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 26: Asia Pacific Women's Health Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 27: Asia Pacific Women's Health Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 28: Asia Pacific America Women's Health Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 29: Asia Pacific Women's Health Market Value Share Analysis, by Disease Indication, 2022 and 2031
  • Figure 30: Asia Pacific Women's Health Market Attractiveness Analysis, by Disease Indication 2023-2031
  • Figure 31: Latin America Women's Health Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 32: Latin America Women's Health Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 33: Latin America Women's Health Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 34: Latin America Women's Health Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 35: Latin America Women's Health Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 36: Middle East & Africa Women's Health Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 37: Middle East & Africa Women's Health Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 38: Middle East & Africa America Women's Health Market Value Share Analysis, by Treatment Type, 2023-2031
  • Figure 39: Middle East & Africa America Women's Health Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 40: Middle East & Africa Women's Health Market Value Share Analysis, by Disease Indication, 2022 and 2031
  • Figure 41: Middle East & Africa Women's Health Market Attractiveness Analysis, by Disease Indication 2023-2031
  • Figure 42: Global Women's Health Market Share Analysis, by Company (2022)